Ligand Pharmaceuticals | LGND - Zysk Brutto





Zysk Brutto Zmiana Data
Agenus USD -10.61M 263.52M 2025-12
Amgen USD 3.92B 2.35B 2025-09
Anika Therapeutics USD 764K 3M 2025-12
Arrowhead Research USD 28.27M 7.85M 2025-12
Baxter International USD 121M 12M 2025-09
Bristol-Myers Squibb USD 3.11B 1.34B 2025-09
Eli Lilly USD 7.23B 456M 2025-09
Enanta Pharmaceuticals USD -22.71M 95.08M 2024-12
Enviri Corporation USD 361.08M 15.18M 2025-09
Gilead Sciences USD 2.08B 1.56B 2025-12
GlaxoSmithKline GBP 1.23B 1.23B 2025-12
Glaxosmithkline GBP 2.46B 569M 2025-09
Heron Therapeutics USD -2.95M 14.54M 2025-12
Insmed USD -326.93M 41.77M 2025-12
Intrexon USD -60.48M 27.09M 2024-06
Ionis Pharmaceuticals USD -228M 99M 2025-12
Karyopharm Therapeutics USD -39.9M 9.01M 2025-12
Ligand Pharmaceuticals USD 141.14M 102M 2025-09
MacroGenics USD -14.93M 31.75M 2025-12
Merck USD 6.74B 22M 2025-09
Pacira USD 9.52M 11.45M 2025-09
Pfizer USD 3.33B 290M 2025-09
Rigel Pharmaceuticals USD -1.03M 7.22M 2024-06
Sangamo BioSciences USD -36.05M 12.94M 2024-06
Veracyte USD 40.63M 21.74M 2025-12